PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatme...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.757 |
| _version_ | 1827698474507829248 |
|---|---|
| author | Marta Ligero Marc Simó Cecilia Carpio Gloria Iacoboni Maria Balaguer‐Montero Victor Navarro Mario Andres Sánchez‐Salinas Sabela Bobillo Ana Marín‐Niebla Josu Iraola‐Truchuelo Pau Abrisqueta Roser Sala‐Llonch Francesc Bosch Raquel Perez‐Lopez Pere Barba |
| author_facet | Marta Ligero Marc Simó Cecilia Carpio Gloria Iacoboni Maria Balaguer‐Montero Victor Navarro Mario Andres Sánchez‐Salinas Sabela Bobillo Ana Marín‐Niebla Josu Iraola‐Truchuelo Pau Abrisqueta Roser Sala‐Llonch Francesc Bosch Raquel Perez‐Lopez Pere Barba |
| author_sort | Marta Ligero |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatment outcomes with the aim of improving patient selection for CAR T‐cell therapy. We conducted a single‐center study including 93 consecutive R/R LBCL patients who received a CAR T‐cell infusion from 2018 to 2021, split in training set (73 patients) and test set (20 patients). Radiomics features were extracted from baseline PET scans and clinical benefit was defined based on median progression‐free survival (PFS). Cox regression models including the radiomics signature, conventional PET biomarkers and clinical variables were performed for most relevant outcomes. A radiomics signature including 4 PET‐based parameters achieved an AUC = 0.73 for predicting clinical benefit in the test set, outperforming the predictive value of conventional PET biomarkers (total metabolic tumor volume [TMTV]: AUC = 0.66 and maximum standardized uptake value [SUVmax]: AUC = 0.59). A high radiomics score was also associated with longer PFS and OS in the multivariable analysis. In conclusion, the PET‐based radiomics signature predicted efficacy of CAR T‐cell therapy and outperformed conventional PET biomarkers in our cohort of LBCL patients. |
| first_indexed | 2024-03-10T13:30:49Z |
| format | Article |
| id | doaj.art-462a685cd00d42bab3c5166896577a04 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-10T13:30:49Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-462a685cd00d42bab3c5166896577a042023-11-21T07:58:46ZengWileyeJHaem2688-61462023-11-01441081108810.1002/jha2.757PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphomaMarta Ligero0Marc Simó1Cecilia Carpio2Gloria Iacoboni3Maria Balaguer‐Montero4Victor Navarro5Mario Andres Sánchez‐Salinas6Sabela Bobillo7Ana Marín‐Niebla8Josu Iraola‐Truchuelo9Pau Abrisqueta10Roser Sala‐Llonch11Francesc Bosch12Raquel Perez‐Lopez13Pere Barba14Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona SpainNuclear Medicine Department Vall d'Hebron University Hospital, Autonomous University of Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainRadiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona SpainOncology Data Science (ODysSey) Group Vall d'Hebron Institute of Oncology (VHIO) Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainFaculty of Medicine Department of Biomedicine Institute of Neurosciences, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainRadiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona SpainDepartment of Hematology Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Barcelona Barcelona SpainAbstract Chimeric antigen receptor (CAR) T‐cell therapy is a promising treatment option for relapsed or refractory (R/R) large B‐cell lymphoma (LBCL). However, only a subset of patients will present long‐term benefit. In this study, we explored the potential of PET‐based radiomics to predict treatment outcomes with the aim of improving patient selection for CAR T‐cell therapy. We conducted a single‐center study including 93 consecutive R/R LBCL patients who received a CAR T‐cell infusion from 2018 to 2021, split in training set (73 patients) and test set (20 patients). Radiomics features were extracted from baseline PET scans and clinical benefit was defined based on median progression‐free survival (PFS). Cox regression models including the radiomics signature, conventional PET biomarkers and clinical variables were performed for most relevant outcomes. A radiomics signature including 4 PET‐based parameters achieved an AUC = 0.73 for predicting clinical benefit in the test set, outperforming the predictive value of conventional PET biomarkers (total metabolic tumor volume [TMTV]: AUC = 0.66 and maximum standardized uptake value [SUVmax]: AUC = 0.59). A high radiomics score was also associated with longer PFS and OS in the multivariable analysis. In conclusion, the PET‐based radiomics signature predicted efficacy of CAR T‐cell therapy and outperformed conventional PET biomarkers in our cohort of LBCL patients.https://doi.org/10.1002/jha2.757CAR T cellsDLBCLnon‐Hodgkin lymphomaPETprogression‐free survivalradiomics |
| spellingShingle | Marta Ligero Marc Simó Cecilia Carpio Gloria Iacoboni Maria Balaguer‐Montero Victor Navarro Mario Andres Sánchez‐Salinas Sabela Bobillo Ana Marín‐Niebla Josu Iraola‐Truchuelo Pau Abrisqueta Roser Sala‐Llonch Francesc Bosch Raquel Perez‐Lopez Pere Barba PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma eJHaem CAR T cells DLBCL non‐Hodgkin lymphoma PET progression‐free survival radiomics |
| title | PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma |
| title_full | PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma |
| title_fullStr | PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma |
| title_full_unstemmed | PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma |
| title_short | PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma |
| title_sort | pet based radiomics signature can predict durable responses to car t cell therapy in patients with large b cell lymphoma |
| topic | CAR T cells DLBCL non‐Hodgkin lymphoma PET progression‐free survival radiomics |
| url | https://doi.org/10.1002/jha2.757 |
| work_keys_str_mv | AT martaligero petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT marcsimo petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT ceciliacarpio petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT gloriaiacoboni petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT mariabalaguermontero petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT victornavarro petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT marioandressanchezsalinas petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT sabelabobillo petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT anamarinniebla petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT josuiraolatruchuelo petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT pauabrisqueta petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT rosersalallonch petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT francescbosch petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT raquelperezlopez petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma AT perebarba petbasedradiomicssignaturecanpredictdurableresponsestocartcelltherapyinpatientswithlargebcelllymphoma |